Literature DB >> 16797265

Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?

Craig M Powell1, Tsuyoshi Miyakawa.   

Abstract

Animal models are extremely useful tools in defining pathogenesis and treatment of human disease. Creating adequate animal models of complex neuropsychiatric disorders such as schizophrenia represents a particularly difficult challenge. In the case of schizophrenia, little is certain regarding the etiology or pathophysiology of the human disease. In addition, many symptoms of the disorder are difficult to measure directly in rodents. These challenges have not daunted neuroscientists who are capitalizing on even subtle overlaps between this uniquely human disorder and rodent behavior. In this perspective, we detail the features of ideal animal models of schizophrenia, the potential utility of such models, and the rodent behaviors used to model certain aspects of schizophrenia. The development of such models will provide critical tools to understand the pathogenesis of schizophrenia and novel insights into therapeutic approaches to this complex disorder.

Entities:  

Mesh:

Year:  2006        PMID: 16797265      PMCID: PMC3928106          DOI: 10.1016/j.biopsych.2006.05.008

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  132 in total

Review 1.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Authors:  Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

Review 2.  Evaluating glutamatergic transmission in schizophrenia.

Authors:  Carol A Tamminga; Adrienne C Lahti; Deborah R Medoff; Xue-Min Gao; Henry H Holcomb
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 3.  Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia.

Authors:  Y Chudasama; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

4.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies.

Authors:  Patrick F Sullivan; Kenneth S Kendler; Michael C Neale
Journal:  Arch Gen Psychiatry       Date:  2003-12

Review 5.  Neurobehavioral assessment in the information age.

Authors:  Laurence H Tecott; Eric J Nestler
Journal:  Nat Neurosci       Date:  2004-05       Impact factor: 24.884

6.  Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.

Authors:  E M Tunbridge; D M Bannerman; T Sharp; P J Harrison
Journal:  J Neurosci       Date:  2004-06-09       Impact factor: 6.167

Review 7.  Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition.

Authors:  M Van den Buuse; B Garner; M Koch
Journal:  Curr Mol Med       Date:  2003-08       Impact factor: 2.222

8.  The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice.

Authors:  Alasdair M Barr; Virginia Lehmann-Masten; Martin Paulus; Raul R Gainetdinov; Marc G Caron; Mark A Geyer
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

9.  The prenatal methylazoxymethanol acetate treatment: a neurodevelopmental animal model for schizophrenia?

Authors:  Ana L Jongen-Rêlo; Andreas Leng; Marcel Lüber; Helen H J Pothuizen; Liz Weber; Joram Feldon
Journal:  Behav Brain Res       Date:  2004-03-02       Impact factor: 3.332

10.  The presynaptic active zone protein RIM1alpha is critical for normal learning and memory.

Authors:  Craig M Powell; Susanne Schoch; Lisa Monteggia; Michel Barrot; Maria F Matos; Nicole Feldmann; Thomas C Südhof; Eric J Nestler
Journal:  Neuron       Date:  2004-04-08       Impact factor: 17.173

View more
  112 in total

1.  Deletion of densin-180 results in abnormal behaviors associated with mental illness and reduces mGluR5 and DISC1 in the postsynaptic density fraction.

Authors:  Holly J Carlisle; Tinh N Luong; Andrew Medina-Marino; Leslie Schenker; Eugenia Khorosheva; Tim Indersmitten; Keith M Gunapala; Andrew D Steele; Thomas J O'Dell; Paul H Patterson; Mary B Kennedy
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

2.  Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.

Authors:  Francesco Matrisciano; Patricia Tueting; Stefania Maccari; Ferdinando Nicoletti; Alessandro Guidotti
Journal:  Neuropsychopharmacology       Date:  2011-11-16       Impact factor: 7.853

3.  Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Authors:  Segev Barak; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

4.  Of rats and schizophrenia.

Authors:  Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2007-01       Impact factor: 6.186

5.  Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.

Authors:  José L Moreno; Mitsumasa Kurita; Terrell Holloway; Javier López; Richard Cadagan; Luis Martínez-Sobrido; Adolfo García-Sastre; Javier González-Maeso
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

6.  Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.

Authors:  Thiago Garcia Varga; Juan Guilherme de Toledo Simões; Amanda Siena; Elisandra Henrique; Regina Cláudia Barbosa da Silva; Vinicius Dos Santos Bioni; Aline Camargo Ramos; Tatiana Rosado Rosenstock
Journal:  Psychopharmacology (Berl)       Date:  2021-06-05       Impact factor: 4.530

7.  Genomic responses in mouse models greatly mimic human inflammatory diseases.

Authors:  Keizo Takao; Tsuyoshi Miyakawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

8.  Defective craniofacial development and brain function in a mouse model for depletion of intracellular inositol synthesis.

Authors:  Tetsuo Ohnishi; Takuya Murata; Akiko Watanabe; Akiko Hida; Hisako Ohba; Yoshimi Iwayama; Kazuo Mishima; Yoichi Gondo; Takeo Yoshikawa
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

9.  Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia.

Authors:  Xiaochuan Guo; Peter J Hamilton; Nicholas J Reish; J David Sweatt; Courtney A Miller; Gavin Rumbaugh
Journal:  Neuropsychopharmacology       Date:  2009-01-14       Impact factor: 7.853

10.  NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.

Authors:  Bo Li; Nino Devidze; Denis Barengolts; Naseem Prostak; Eleana Sphicas; Alfonso J Apicella; Roberto Malinow; Effat S Emamian
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.